Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

GNLX

Genelux Corp

Feb 13 • 12:55PM ET

2.61

+0.12 4.82 %

Healthcare • Biotechnology • USA • NASD

Peers: LLY VRTX MRNA REGN PFE NVS GILD BMY AMGN BIIB

| Held by: VTI VXF IWC DFAC RFLR BTEC CHNA

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	11.00%	Shs Outstand	44.72M	Perf Week	9.21%
Market Cap	116.72M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	-0.75%	Shs Float	39.80M	Perf Month	0.00%
Enterprise Value	97.43M	PEG	-	EPS next Q	-0.22	Inst Own	27.45%	Short Float	7.93%	Perf Quarter	-55.99%
Income	-31.87M	P/S	-	EPS this Y	10.88%	Inst Trans	1.28%	Short Ratio	12.97	Perf Half Y	-23.46%
Sales	0.00M	P/B	5.28	EPS next Y	-10.43%	ROA	-97.69%	Short Interest	3.16M	Perf YTD	-40.14%
Book/sh	0.49	P/C	5.58	EPS next 5Y	2.61%	ROE	-123.35%	52W High	8.53 -69.42%	Perf Year	-52.20%
Cash/sh	0.47	P/FCF	-	EPS past 3/5Y	-11.05% -14.03%	ROIC	-160.49%	52W Low	1.99 31.32%	Perf 3Y	-57.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.50% 7.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	7.80%	Oper. Margin	-	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.20	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	40.08	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.20	EPS Q/Q	-12.01%	SMA20	-1.86%	Beta	0.26	Target Price	19.33
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	-23.88%	Rel Volume	0.86	Prev Close	2.49
Employees	24	LT Debt/Eq	0.07	Earnings	Nov 05 AMC	SMA200	-32.13%	Avg Volume	243.38K	Price	2.61
IPO	Jan 26, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.55% -	Trades		Volume	115,167	Change	4.82%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-21-25	Initiated	Lake Street	Buy	$16
Oct-29-24	Initiated	Guggenheim	Buy	$8
Aug-28-24	Initiated	ROTH MKM	Buy	$10
Nov-27-23	Initiated	H.C. Wainwright	Buy	$35
Sep-12-23	Initiated	Maxim Group	Buy	$40
Feb-15-23	Initiated	The Benchmark Company	Speculative Buy	$10

Jan-12-26 04:00PM	Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners (GlobeNewswire) -5.36%
Jan-08-26 09:13AM	Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.76%
Jan-07-26 04:01PM	Genelux Corporation Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-05-26 08:00AM	Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials (GlobeNewswire) -23.52%
Jan-02-26 08:00AM	Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer (GlobeNewswire)
08:00AM	Loading…
Nov-26-25 08:00AM	Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.67%
Nov-05-25 04:20PM	Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -32.40%
Sep-02-25 04:01PM	Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-07-25 04:20PM	Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -6.96% -5.69%
Jul-07-25 07:00AM	Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development (GlobeNewswire)
Jun-02-25 12:00PM	Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know (Zacks)
May-06-25 04:10PM	Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates (GlobeNewswire) -7.17%
May-01-25 04:05PM	Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference (GlobeNewswire) -9.85% +8.45%
Apr-18-25 09:40AM	Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 04:10PM	Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -12.34%
09:35AM	Loading…
09:35AM	Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Mar-25-25 08:31AM	Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock (GlobeNewswire) -12.60%
08:30AM	Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease (GlobeNewswire)
08:30AM	Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer (GlobeNewswire)
Mar-02-25 09:39AM	Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-03-25 06:45AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) -10.63%
Dec-13-24 07:01AM	Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright (GlobeNewswire) -7.54%
Nov-15-24 09:50AM	These 2 Strong Buy Penny Stocks Are Set to Triple (or more), Say Analysts (TipRanks) -19.73%
Nov-14-24 04:05PM	Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Nov-06-24 04:01PM	Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference (GlobeNewswire)
Oct-25-24 01:01PM	Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp (GuruFocus.com)
Oct-23-24 11:27AM	Genelux doses first subject in Phase II trial of NSCLC treatment (Clinical Trials Arena)
Oct-22-24 04:01PM	Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-09-24 04:15PM	Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-03-24 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +13.94%
09:54PM	Loading…
Aug-14-24 09:54PM	GNLX Stock Earnings: Genelux Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-12-24 05:16PM	Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds (Insider Monkey) -6.57%
Jul-30-24 07:00AM	Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2024 (GlobeNewswire)
May-24-24 08:00AM	Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants (GlobeNewswire) -43.04%
May-23-24 04:01PM	Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire) -5.35%
May-09-24 11:53PM	GNLX Stock Earnings: Genelux Misses EPS for Q1 2024 (InvestorPlace) +6.07%
04:25PM	Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates (GlobeNewswire)
Apr-26-24 09:35AM	Down -48.37% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-23-24 09:35AM	Down -45.44% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround (Zacks)
Apr-05-24 09:35AM	After Plunging -26.21% in 4 Weeks, Here's Why the Trend Might Reverse for Genelux Corporation (GNLX) (Zacks)
Apr-04-24 12:00PM	All You Need to Know About Genelux Corporation (GNLX) Rating Upgrade to Buy (Zacks)
Apr-02-24 07:52AM	GNLX Stock Earnings: Genelux Misses EPS for Q4 2023 (InvestorPlace)
Apr-01-24 07:00AM	Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -18.51%
Dec-15-23 03:01PM	Insider Sell Alert: Director James Tyree Offloads 9,000 Shares of Genelux Corp (GNLX) (GuruFocus.com) -13.23%
Nov-27-23 07:00AM	Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer (GlobeNewswire)
Nov-14-23 05:50PM	Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire) -7.61%
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-11-23 09:00AM	Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment (PR Newswire)
Sep-19-23 03:01PM	Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX) (GuruFocus.com) +8.04%
Sep-15-23 03:03PM	Director John Smither Sells 900 Shares of Genelux Corp (GNLX) (GuruFocus.com)
Sep-14-23 01:21PM	10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX) (GuruFocus.com)
07:00AM	Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 04:01PM	Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -6.69%
Aug-28-23 07:00AM	Genelux Corporation Announces New Chief Financial Officer (GlobeNewswire) +11.01%
Aug-14-23 07:00AM	Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates (GlobeNewswire)
Aug-02-23 04:00PM	Genelux Corporation to Participate in Fireside Chat at BTIGs Virtual Biotechnology Conference 2023 (GlobeNewswire) +5.52%
01:08AM	10 Recent IPOs in 2023 to Consider (Insider Monkey)
Jul-28-23 10:54AM	Why Shares of Genelux Climbed This Week (Motley Fool) -9.38%
Jul-20-23 04:45PM	Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires (GlobeNewswire) -10.85% -15.77%
Jul-10-23 07:00AM	Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology (GlobeNewswire)
Jun-29-23 07:00AM	Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC (GlobeNewswire)
Jun-22-23 07:00AM	Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023 (GlobeNewswire) -7.05%
Jun-12-23 07:00AM	Genelux Corporation Announces $18 Million Private Placement (GlobeNewswire) +7.58%
Jun-01-23 05:19PM	Why Shares of Genelux Corporation Jumped This Week (Motley Fool) +6.62%
May-25-23 04:01PM	Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology (GlobeNewswire) +6.62%
May-15-23 07:00AM	Genelux Corporation Announces $33 Million Private Placement (GlobeNewswire) -9.06%
Mar-23-23 07:00AM	Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023 (GlobeNewswire)
Jan-25-23 09:00PM	Genelux Corporation Announces Pricing of Initial Public Offering (GlobeNewswire)

Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Yu Yong	SVP, Clinical Development	Aug 21 '25	Sale	3.36	3,219	10,807	146,817	Dec 11 08:50 PM
Yu Yong	SVP, Clinical Development	Nov 17 '25	Sale	5.37	973	5,224	145,844	Dec 11 08:50 PM
Zindrick Thomas	President and CEO	Aug 21 '25	Sale	3.33	12,673	42,159	542,940	Dec 11 08:50 PM
Zindrick Thomas	President and CEO	Nov 17 '25	Sale	5.37	4,509	24,211	538,431	Dec 11 08:50 PM
Cappello Joseph	Chief Technical Officer	Aug 21 '25	Sale	3.34	2,733	9,137	157,033	Dec 11 08:49 PM
Cappello Joseph	Chief Technical Officer	Nov 17 '25	Sale	5.37	973	5,224	156,060	Dec 11 08:49 PM
Smalling Ralph	Head of Regulatory	Aug 21 '25	Sale	3.36	1,244	4,177	69,746	Dec 09 08:00 PM
Smalling Ralph	Head of Regulatory	Sep 03 '25	Sale	3.36	580	1,948	69,166	Dec 09 08:00 PM
Smalling Ralph	Head of Regulatory	Nov 17 '25	Sale	5.37	343	1,842	68,823	Dec 09 08:00 PM
Smalling Ralph	Head of Regulatory	Dec 05 '25	Sale	4.69	165	774	68,658	Dec 09 08:00 PM
Thomas John	Director	Dec 01 '25	Sale	5.00	10,000	50,008	492,784	Dec 02 07:00 PM
JOHNNY THOMAS	Director	Dec 01 '25	Proposed Sale	5.56	10,000	55,600		Dec 01 04:34 PM
Ryder Sean	General Counsel	May 12 '25	Sale	2.92	4,475	13,067	47,621	May 13 05:05 PM
Zindrick Thomas	President and CEO	May 12 '25	Sale	2.92	10,764	31,431	191,447	May 13 05:05 PM
Yu Yong	VP, Clinical Trial Operations	May 12 '25	Sale	2.92	5,579	16,291	47,640	May 13 05:05 PM
Cappello Joseph	VP, Pharmaceutical Development	May 12 '25	Sale	2.92	4,737	13,832	52,266	May 13 05:05 PM
Smalling Ralph	Head of Regulatory	May 12 '25	Sale	2.92	1,259	3,676	34,760	May 13 05:05 PM

ASRT Assertio Holdings Inc daily Stock Chart

Peers: SFM OIS DCTH HRTX PBPB MYE OPI NUS FET TSE

| Held by: VTI VXF BSVO RFLR

Index	-	P/E	-	EPS (ttm)	-4.71	Insider Own	2.61%	Shs Outstand	6.42M	Perf Week	-4.04%
Market Cap	78.45M	Forward P/E	-	EPS next Y	-2.57	Insider Trans	-5.08%	Shs Float	6.25M	Perf Month	19.74%
Enterprise Value	29.99M	PEG	-	EPS next Q	-3.12	Inst Own	26.98%	Short Float	4.29%	Perf Quarter	-5.76%
Income	-28.92M	P/S	0.57	EPS this Y	-73.70%	Inst Trans	0.79%	Short Ratio	5.55	Perf Half Y	-0.40%
Sales	137.35M	P/B	0.74	EPS next Y	57.07%	ROA	-9.71%	Short Interest	0.27M	Perf YTD	34.79%
Book/sh	16.49	P/C	0.84	EPS next 5Y	-	ROE	-24.48%	52W High	15.15 -19.31%	Perf Year	-4.68%
Cash/sh	14.56	P/FCF	5.88	EPS past 3/5Y	-96.92% 55.01%	ROIC	-19.22%	52W Low	7.71 58.65%	Perf 3Y	-83.20%
Dividend Est.	-	EV/EBITDA	2.14	Sales past 3/5Y	4.02% -11.45%	Gross Margin	45.68%	Volatility	7.19% 6.52%	Perf 5Y	-82.13%
Dividend TTM	-	EV/Sales	0.22	EPS Y/Y TTM	58.12%	Oper. Margin	-12.29%	ATR (14)	0.67	Perf 10Y	-98.73%
Dividend Ex-Date	-	Quick Ratio	1.43	Sales Y/Y TTM	9.21%	Profit Margin	-21.06%	RSI (14)	57.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.58	EPS Q/Q	450.85%	SMA20	2.72%	Beta	0.72	Target Price	37.44
Payout	-	Debt/Eq	0.43	Sales Q/Q	69.36%	SMA50	10.77%	Rel Volume	0.24	Prev Close	12.21
Employees	58	LT Debt/Eq	0.42	Earnings	Nov 10 AMC	SMA200	9.28%	Avg Volume	48.30K	Price	12.23
IPO	Dec 02, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	229.41% 83.05%	Trades		Volume	6,324	Change	0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Initiated	Maxim Group	Buy	$3
Jul-03-24	Initiated	H.C. Wainwright	Buy	$4
Nov-07-22	Initiated	Lake Street	Buy	$7
Nov-30-18	Downgrade	Mizuho	Buy → Neutral

Feb-12-26 08:10AM	Zoetis (ZTS) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-10-26 10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
Feb-06-26 11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks) +9.64%
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
11:59AM	Loading…
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
06:28AM	Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? (Zacks)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:55AM	Wall Street Analysts See a 230.56% Upside in Assertio (ASRT): Can the Stock Really Move This High? (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
09:40AM	Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year? (Zacks)
Jan-16-26 09:55AM	Wall Street Analysts Think Assertio (ASRT) Could Surge 249.87%: Read This Before Placing a Bet (Zacks)
Jan-14-26 09:40AM	Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-12-26 04:15PM	Assertio Holdings, Inc. Regains Compliance With Nasdaq Listing Requirements (Business Wire) +10.89%
Jan-09-26 01:45PM	Assertio Announces Publication of Rolvedon Same-Day Dosing Clinical Trial (Business Wire)
04:30PM	Loading…
Dec-22-25 04:30PM	Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split (Business Wire) -9.81%
Nov-11-25 04:01AM	Assertio Holdings Inc (ASRT) Q3 2025 Earnings Call Highlights: Impressive Growth Amid Market ... (GuruFocus.com) +14.89%
Nov-10-25 05:45PM	Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +5.33%
04:41PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance)
04:13PM	Assertio Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-06-25 08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
Oct-28-25 09:15AM	Assertio Announces Leadership Transition (GlobeNewswire)
Sep-23-25 05:04AM	New Strong Sell Stocks for September 23rd (Zacks)
Sep-19-25 06:23AM	New Strong Sell Stocks for September 19th (Zacks) -7.22%
Sep-16-25 04:59AM	New Strong Sell Stocks for September 16th (Zacks)
Sep-15-25 09:00AM	Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN (clobazam) Oral Film, CIV (GlobeNewswire)
Sep-10-25 07:30AM	Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN at upcoming 150th Annual Meeting of the American Neurological Association (GlobeNewswire)
Sep-03-25 08:15AM	Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025 (GlobeNewswire)
Aug-26-25 06:17AM	New Strong Sell Stocks for August 26th (Zacks)
Aug-12-25 03:06AM	Assertio Holdings Inc (ASRT) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +13.85%
06:55PM	Loading…
Aug-11-25 06:55PM	Assertio (ASRT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
05:54PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Assertio Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-08-25 09:31AM	Assertio Holdings Inc (ASRT) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-06-25 03:41PM	Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors (PR Newswire)
08:30AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 08:30AM	Assertio Holdings, Inc. to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-08-25 06:28AM	New Strong Sell Stocks for July 8th (Zacks)
Jun-30-25 06:03AM	New Strong Sell Stocks for June 30th (Zacks)
Jun-25-25 06:26AM	New Strong Sell Stocks for June 25th (Zacks)
Jun-18-25 05:08AM	New Strong Sell Stocks for June 18th (Zacks)
May-19-25 04:10PM	Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025 (GlobeNewswire) +6.77%
May-13-25 05:38AM	Q1 2025 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Assertio Holdings Inc (ASRT) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Assertio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-09-25 09:48AM	Assertio Holdings Inc (ASRT) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-05-25 08:15AM	Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire) -6.46%
Apr-07-25 09:17AM	Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains? (Zacks) -6.19%
Mar-21-25 09:00AM	iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 (ACCESSWIRE)
Mar-20-25 09:10AM	Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025 (GlobeNewswire)
Mar-13-25 12:58PM	Q4 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -7.46%
03:08AM	Assertio Holdings Inc (ASRT) Q4 2024 Earnings Call Highlights: Strategic Growth Amidst Challenges (GuruFocus.com)
Mar-12-25 04:30PM	Assertio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Assertio Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-05-25 04:05PM	Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025 (GlobeNewswire) +6.49%
Jan-03-25 04:30PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-17-24 08:30AM	Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors (GlobeNewswire)
Dec-13-24 08:00AM	Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study (GlobeNewswire)
Dec-12-24 08:00AM	Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO (GlobeNewswire)
Dec-06-24 07:00AM	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer (GlobeNewswire)
Nov-15-24 09:00AM	Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio (Business Wire)
Nov-12-24 09:41AM	Q3 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -7.89%
Nov-11-24 04:09PM	Assertio: Q3 Earnings Snapshot (Associated Press Finance) +8.82%
04:02PM	Assertio Reports Third Quarter 2024 Financial Results (GlobeNewswire)
03:41PM	Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio (Business Wire)
07:30AM	Assertio Provides Response to Letter from Short-seller (GlobeNewswire)
Nov-08-24 09:00AM	Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud (Business Wire) -15.84%
07:06AM	Assertio Holdings Inc (ASRT) Q3 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Oct-30-24 08:00AM	Assertio Holdings, Inc. to Report Third Quarter 2024 Financial Results on November 11, 2024 (GlobeNewswire)
Oct-11-24 08:00AM	Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024 (GlobeNewswire)
Oct-09-24 05:18PM	Assertio Holdings Inc (ASRT) Q2 2024 Earnings Call Highlights: Navigating Sales Challenges and ... (GuruFocus.com)
Oct-04-24 04:05PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-24 04:05PM	Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024 (GlobeNewswire) -5.93% +10.81%
Aug-07-24 04:47PM	Assertio: Q2 Earnings Snapshot (Associated Press Finance) -11.79%
04:01PM	Assertio Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-24-24 04:05PM	Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire) -6.17%
09:00AM	Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc. (Business Wire)
Jul-09-24 04:30PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +8.11%
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-06-24 04:05PM	Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 08:30AM	Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024 (GlobeNewswire)
May-29-24 07:00AM	Assertio Announces the Appointment of Brendan P. O'Grady as New CEO (GlobeNewswire)
May-17-24 09:15AM	Assertio to Participate in Benchmark Healthcare Conference on May 21-22 (GlobeNewswire)
07:30AM	BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS (PR Newswire)
May-16-24 09:16AM	Assertio to Participate in AGP Healthcare Conference on May 21 (GlobeNewswire)
May-13-24 05:52PM	BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE 'AGAINST' DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS (PR Newswire) +9.38%
May-10-24 03:12PM	Assertio to Present at the Citizens JMP Life Sciences Conference in New York City (GlobeNewswire) -8.57%
May-07-24 10:28AM	Assertio Holdings, Inc. (NASDAQ:ASRT) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.02%
05:35AM	Q1 2024 Assertio Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
03:10AM	Assertio Holdings Inc (ASRT) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
May-06-24 08:59PM	ASRT Stock Earnings: Assertio Holdings Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +18.45%
05:46PM	Assertio Holdings Inc (ASRT) Surpasses Revenue Estimates But Reports Wider Loss in Q1 2024 (GuruFocus.com)
04:21PM	Assertio: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Assertio Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 08:00AM	Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire) -9.30%
Apr-03-24 08:00AM	Sig Kirk Joins Assertio Board of Directors (GlobeNewswire)
Apr-01-24 09:00AM	Assertio to Present at LD Micro Invitational Conference in New York City (GlobeNewswire)

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schlessinger Sam	EVP, General Counsel	Feb 07 '26	Option Exercise	0.00	1,389	0	13,185	Feb 10 06:27 PM
Schwichtenberg Paul	President and COO	Feb 07 '26	Option Exercise	0.00	1,666	0	12,834	Feb 10 06:27 PM
Patel Ajay	EVP and CFO	Feb 07 '26	Option Exercise	0.00	1,666	0	14,789	Feb 10 06:26 PM
Stark David Matthew	Director	Nov 10 '25	Sale	0.76	8,959	6,806	98,541	Nov 12 06:00 PM
DAVID STARK	Director	Nov 10 '25	Proposed Sale	0.76	8,959	6,806		Nov 10 04:07 PM
O'Grady Brendan P.	CEO	May 31 '25	Option Exercise	0.00	166,665	0	178,371	Jun 03 06:00 PM
Schlessinger Sam	EVP, General Counsel	May 12 '25	Option Exercise	0.00	38,017	0	191,906	May 14 06:03 PM
Schwichtenberg Paul	See Remarks	May 12 '25	Option Exercise	0.00	38,017	0	184,362	May 14 06:01 PM
Patel Ajay	EVP and CFO	May 12 '25	Option Exercise	0.00	38,017	0	213,692	May 14 06:00 PM
Schlessinger Sam	SVP, General Counsel	Feb 21 '25	Option Exercise	0.00	17,150	0	161,545	Feb 25 06:03 PM
Schwichtenberg Paul	See Remarks	Feb 21 '25	Option Exercise	0.00	17,150	0	154,850	Feb 25 06:02 PM
Patel Ajay	SVP and CFO	Feb 21 '25	Option Exercise	0.00	17,150	0	184,180	Feb 25 06:00 PM

GNLX

Genelux Corp

ASRT

Assertio Holdings Inc

Upgrade your FINVIZ experience